Resverlogix Corp.
Resverlogix Corp. (RVXCF) Company Profile & Overview
Explore Resverlogix Corp.’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.
Resverlogix Corp. (RVXCF) Company Profile & Overview
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. It is developing apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada. The company is headquartered in Calgary, Canada.